Identification of a serum biomarker signature associated with metastatic prostate cancer. Issue 2 (4th May 2021)

• Record Type: Journal Article
• Authors: Kuci Emruli, Venera; Liljedahl, Leena; Axelsson, Ulrika; Richter, Corinna; Theorin, Lisa; Bjartell, Anders; Lilja, Hans; Donovan, Jenny; Neal, David; Hamdy, Freddie C.; Borrebaeck, Carl A. K.
• Is Part Of: Proteomics. Volume 15:Issue 2/3(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-05-04
• Subjects: affinity proteomics -- antibody microarrays -- biomarkers -- cancer -- prostate cancer; Proteomics -- Periodicals; 572.605
• DOI: 10.1002/prca.202000025
• Languages: English
• ISSNs: 1862-8346

Abstract

Abstract: Purpose: Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over‐treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease. Experimental design: In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non‐metastatic PC and patients with metastatic PC, using a recombinant antibody microarray. Results: A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified. Conclusions and clinical relevance: The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.